LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Deep brain stimulation in a young child with

    Fung, Eva Lai-Wah / Mo, Chung-Yin / Fung, Sharon Tsui-Hang / Chan, Anne Yin-Yan / Lau, Ka-Yee / Chan, Emily Kit-Ying / Chan, David Yuen-Chung / Zhu, Xian-Lun / Chan, Danny Tat-Ming / Poon, Wai-Sang

    Surgical neurology international

    2022  Volume 13, Page(s) 285

    Abstract: Background: GNAO1: Case description: A 4-year-old girl diagnosed to have : Conclusion: DBS should be considered early in the treatment of drug-resistant movement disorders in young children ... ...

    Abstract Background: GNAO1
    Case description: A 4-year-old girl diagnosed to have
    Conclusion: DBS should be considered early in the treatment of drug-resistant movement disorders in young children with
    Language English
    Publishing date 2022-07-01
    Publishing country United States
    Document type Case Reports
    ISSN 2229-5097
    ISSN 2229-5097
    DOI 10.25259/SNI_166_2022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Guillain-Barré syndrome in children - High occurrence of Miller Fisher syndrome in East Asian region.

    Chiu, Annie Ting Gee / Chan, Ricky Wing Ki / Yau, Maggie Lo Yee / Yuen, Angus Chi Lap / Lam, Alva King Fai / Lau, Shirley Wai Yin / Lau, Alan Ming Chung / Fung, Sharon Tsui Hang / Ma, Kam Hung / Lau, Christine Wai Ling / Yau, Man Mut / Ko, Chun Hung / Tsui, Kwing Wan / Ma, Che Kwan / Tai, Shuk Mui / Yau, Eric Kin Cheong / Fung, Eva / Wu, Shun Ping / Kwong, Karen Ling /
    Chan, Sophelia Hoi Shan

    Brain & development

    2022  Volume 44, Issue 10, Page(s) 715–724

    Abstract: Background: Guillain-Barré syndrome (GBS) is a rare acquired immune-mediated polyneuropathy. Updated population-based data concerning paediatric GBS is needed.: Methods: Paediatric patients aged below 18 years diagnosed with GBS between 2009 and 2018 ...

    Abstract Background: Guillain-Barré syndrome (GBS) is a rare acquired immune-mediated polyneuropathy. Updated population-based data concerning paediatric GBS is needed.
    Methods: Paediatric patients aged below 18 years diagnosed with GBS between 2009 and 2018 in all 11 paediatric departments in Hong Kong were identified from the Hong Kong Hospital Authority Clinical Data Analysis and Reporting System. The collected data from medical health records were reviewed by paediatric neurologist from each department. Estimated incidence of paediatric GBS was calculated. We also compared our findings with other paediatric GBS studies in Asia.
    Results: 63 subjects of paediatric GBS were identified, giving an estimated annual incidence of 0.62 per 100,000 population. Half of the subjects had acute inflammatory demyelinating polyneuropathy (AIDP) (n = 31; 49.2%), one quarter had Miller Fisher Syndrome (MFS) (n = 16; 25.4%), one-fifth had axonal types of GBS (n = 12; 19.0%), and four were unclassified. Paediatric subjects with axonal subtypes of GBS compared to the other 2 subtypes, had significantly higher intensive care unit (ICU) admission rates (p = 0.001) and longest length of stay (p = 0.009). With immunomodulating therapy, complete recovery was highest in those with MFS (100%), followed by AIDP (87.1%) and axonal GBS (75%). Our study also confirms a higher MFS rate for paediatric GBS in East Asia region and our study has the highest MFS rate (25.4%).
    Conclusion: Our population-based 10-year paediatric GBS study provides updated evidence on estimated incidence, healthcare burden and motor outcome of each subtype of paediatric GBS and confirmed a higher occurrence of paediatric MFS in East Asia.
    MeSH term(s) Humans ; Child ; Aged ; Miller Fisher Syndrome/epidemiology ; Guillain-Barre Syndrome/diagnosis ; Axons ; Incidence ; Hong Kong/epidemiology
    Language English
    Publishing date 2022-07-26
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 604822-5
    ISSN 1872-7131 ; 0387-7604
    ISSN (online) 1872-7131
    ISSN 0387-7604
    DOI 10.1016/j.braindev.2022.07.003
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Anti-N-methyl-d-aspartate receptor encephalitis in children: Incidence and experience in Hong Kong.

    Ho, Alvin Chi-Chung / Chan, Sophelia Hoi-Shan / Chan, Eric / Wong, Sheila Suet-Na / Fung, Sharon Tsui-Hang / Cherk, Sharon Wan-Wah / Fung, Eva Lai-Wah / Ma, Kam-Hung / Tsui, Kwing-Wan / Yau, Eric Kin-Cheong / Wong, Virginia Chun-Nei

    Brain & development

    2018  Volume 40, Issue 6, Page(s) 473–479

    Abstract: Aim: The study aims to analyze the incidence, clinical features, investigation findings and treatment outcomes of anti-N-methyl-d-aspartate receptor encephalitis in children from Hong Kong.: Method: A retrospective study was carried out on paediatric ...

    Abstract Aim: The study aims to analyze the incidence, clinical features, investigation findings and treatment outcomes of anti-N-methyl-d-aspartate receptor encephalitis in children from Hong Kong.
    Method: A retrospective study was carried out on paediatric patients diagnosed with anti-NMDAR encephalitis in Hong Kong from January 2009 to December 2015.
    Results: Fifteen patients (67% female, 93% Chinese) were identified over seven years and the estimated incidence in Hong Kong was 2.2/million children per year (95% CI 1.2-3.6). The median age of presentation was 12 years (range 1-17 years). The most common symptom groups observed were abnormal psychiatric behavior or cognitive dysfunction (14/15, 93%) and seizures (14/15, 93%), followed by speech dysfunction (13/15, 87%), movement disorders (12/15, 80%), decreased level of consciousness (10/15, 67%) and autonomic dysfunction or central hypoventilation (5/15, 33%). The median number of symptom groups developed in each patient was 5 (range 3-6). All patients were treated with intravenous immunoglobulin and/or steroids. Three patients (20%) with more severe presentation required additional plasmapheresis and rituximab. Outcome was assessable in 14 patients. Among those eleven patients who had only received intravenous immunoglobulin and/or steroids, nine patients (82%) achieved full recovery. One patient (9%) had residual behavioral problem, while another one (9%) who developed anti-NMDAR encephalitis after herpes simplex virus encephalitis was complicated with dyskinetic cerebral palsy and epilepsy. Among those three patients who required plasmapheresis and rituximab, one (33%) had full recovery and two (66%) had substantial recovery. The median duration of follow up was 20.5 months (range 3-84 months).
    Conclusion: Anti-NMDAR encephalitis is an acquired, severe, but potentially treatable disorder. Ethnicity may play a role in the incidence of anti-NMDAR encephalitis and we have provided a local incidence with the majority of patients being Chinese. The diagnosis of anti-NMDAR encephalitis should be considered in children presenting with a constellation of symptoms including psychiatric and neurological manifestations. Patients may respond to first line immunotherapy. For those who do not, second line therapy is indicated in order to achieve a better outcome.
    MeSH term(s) Adolescent ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/epidemiology ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/physiopathology ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/psychology ; Anti-N-Methyl-D-Aspartate Receptor Encephalitis/therapy ; Child ; Child, Preschool ; Female ; Follow-Up Studies ; Hong Kong/epidemiology ; Humans ; Incidence ; Infant ; Male ; Retrospective Studies ; Treatment Outcome
    Language English
    Publishing date 2018-03-26
    Publishing country Netherlands
    Document type Journal Article
    ZDB-ID 604822-5
    ISSN 1872-7131 ; 0387-7604
    ISSN (online) 1872-7131
    ISSN 0387-7604
    DOI 10.1016/j.braindev.2018.02.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top